Lipid mediators in diabetic nephropathy.

Lipid mediators in diabetic nephropathy.
复制标题

DOI:
10.1186/1755-1536-7-12
复制
发表时间:
2014
期刊:
Fibrogenesis & tissue repair
影响因子:
--
通讯作者:
Kanasaki K
Kanasaki K
中科院分区:
其他
文献类型:
--
作者:
Srivastava SP;Shi S;Koya D;Kanasaki K

文献摘要

参考文献

被引文献

相似文献

降脂药物在糖尿病肾病治疗中的意义已被考虑。与此同时,降脂药物的临床疗效已导致慢性肾脏病(CKD)伴或不伴糖尿病患者的心血管功能改善,但未观察到肾脏结局的显著改善。早期脂质介质已被证明在糖尿病肾病(DN)中引起累积效应。在此,我们试图分析脂质介质在DN中的参与。高血糖诱导的二酰甘油(diacyglycerol,DAG)的过度产生是蛋白激酶C(protein kinase C,PKCs)激活的原因之一,PKCs激活VEGF、TGFβ1、派-1、NADPH氧化酶和NF κ B B信号通路,加速DN的发生发展。此外,目前对神经酰胺作用的研究是DN的主要研究领域之一。研究人员已经报道了在DN的病理生物学条件下过度的神经酰胺形成。降脂药物对降低PKC激活和神经酰胺合成的影响报道较少。调节PKC的活化和神经酰胺的合成可能是DN治疗潜力的保护措施。降脂药物还上调抗纤维化microRNA,这可能暗示降脂药物在DN中的作用。
The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered. At the same time, the clinical efficacy of lipid lowering drugs has resulted in improvement in the cardiovascular functions of chronic kidney disease (CKD) patients with or without diabetes, but no remarkable improvement has been observed in the kidney outcome. Earlier lipid mediators have been shown to cause accumulative effects in diabetic nephropathy (DN). Here, we attempt to analyze the involvement of lipid mediators in DN. The hyperglycemia-induced overproduction of diacyglycerol (DAG) is one of the causes for the activation of protein kinase C (PKCs), which is responsible for the activation of pathways, including the production of VEGF, TGFβ1, PAI-1, NADPH oxidases, and NFҟB signaling, accelerating the development of DN. Additionally, current studies on the role of ceramide are one of the major fields of study in DN. Researchers have reported excessive ceramide formation in the pathobiological conditions of DN. There is less report on the effect of lipid lowering drugs on the reduction of PKC activation and ceramide synthesis. Regulating PKC activation and ceramide biosynthesis could be a protective measure in the therapeutic potential of DN. Lipid lowering drugs also upregulate anti-fibrotic microRNAs, which could hint at the effects of lipid lowering drugs in DN.
DOI: 10.1038/ncb2441
发表时间: 2012-03-01
影响因子: 21.3
作者:
Hergenreider, Eduard;Heydt, Susanne;Dimmeler, Stefanie
通讯作者: Dimmeler, Stefanie
DOI: 10.1515/bchm3.1994.375.7.447
发表时间: 1994-07-01
期刊: BIOLOGICAL CHEMISTRY HOPPE-SEYLER
影响因子: --
作者:
HURWITZ, R;FERLINZ, K;SANDHOFF, K
通讯作者: SANDHOFF, K
DOI: 10.1053/j.ajkd.2004.11.015
发表时间: 2005-03-01
影响因子: 13.2
作者:
Baigent, C;Landray, M;Wheeler, DC
通讯作者: Wheeler, DC
DOI: 10.1016/j.phrs.2013.03.007
发表时间: 2013-06-01
影响因子: 9.3
作者:
Barylski, Marcin;Nikfar, Shekoufeh;Banach, Maciej
通讯作者: Banach, Maciej
DOI: 10.2337/diacare.26.5.1402
发表时间: 2003-05-01
期刊: DIABETES CARE
影响因子: 16.2
作者:
Appel, GB;Radhakrishnan, J;Brenner, BM
通讯作者: Brenner, BM